Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 82.3%

Neg 0% Neu 0% Pos 82.3%

Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.